Go to the list of all blogs
Arthur Evans's Avatar
published in Blogs
Jul 22, 2026
AMERISAFE (AMSF) Reports +11.4% Premium Growth in Q2

AMERISAFE (AMSF) Reports +11.4% Premium Growth in Q2

Key Takeaways

  • Net premiums earned rose 11.4% year-over-year to $269.7 million.
  • Net income reached $14.6 million, or $0.78 per share.
  • Operating net income was $8.3 million, or $0.44 per share.
  • Return on average equity stood at 11.4% for the quarter.
  • Results reflect continued expansion in high-hazard workers’ compensation lines.

Why These Results Matter

AMERISAFE, Inc. specializes in workers’ compensation insurance for high-hazard industries. Its quarterly results provide insight into underwriting trends, premium pricing power, and loss ratios in a niche market. Investors track these figures closely because sustained premium growth can signal expanding demand and pricing discipline, while any shifts in loss experience directly affect profitability and capital returns in the insurance sector.

Q2 Results Breakdown

For the second quarter ended June 30, 2026, AMERISAFE reported net premiums earned of $269.7 million, an 11.4% increase from the prior-year period. Net income totaled $14.6 million, or $0.78 per diluted share. Operating net income, which excludes certain investment gains and losses, came in at $8.3 million, or $0.44 per share. The company posted a return on average equity of 11.4%.

Compared with consensus expectations, the reported net income exceeded analyst forecasts, while the operating earnings figure aligned closely with projections. Premium growth outpaced recent quarters and contributed positively to top-line momentum. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

How the Market Responded

Shares of AMERISAFE traded higher in the sessions following the July 21 release, reflecting investor focus on the solid premium expansion. Market participants viewed the results as evidence of resilient demand in the company’s specialized insurance niche, with limited negative surprises on the underwriting side.

What to Watch Going Forward

Investors will watch for updates on loss ratios and claims frequency in high-hazard industries. Continued premium growth will depend on the company’s ability to maintain pricing discipline amid competitive pressures.

Management commentary on expense management and investment income trends will help clarify margin sustainability. Broader economic conditions affecting construction, manufacturing, and energy sectors could influence future policy renewals and loss experience.

Upcoming catalysts include any revisions to full-year guidance and details from the earnings conference call regarding reserve development and capital allocation plans. From what I see, these factors will be key to assessing whether the recent momentum holds.

Using AI Tools for Deeper Analysis

In my own review of the results, I turned to Tickeron’s AI Screener to quickly compare AMERISAFE’s metrics against peers in the insurance space. The tool allowed me to filter for similar companies based on premium trends, profitability, and technical signals, which helped put the quarter into better context without spending hours on manual research. It’s become a regular part of how I evaluate specialized insurers like this one.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: AMSF

Contributor

Financial writer and active order flow futures trader with a focus on fundamental analysis, macroeconomic factors, and equity research. I make in-depth blogs on stocks and ETFs, bridging the gap between raw market data and real-world trading decisions.


AMSF's RSI Oscillator is remaining in oversold zone for 1 day

It is expected that a price bounce should occur soon.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where AMSF advanced for three days, in of 295 cases, the price rose further within the following month. The odds of a continued upward trend are .

AMSF may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on July 15, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on AMSF as a result. In of 90 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for AMSF turned negative on July 15, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 45 similar instances when the indicator turned negative. In of the 45 cases the stock turned lower in the days that followed. This puts the odds of success at .

AMSF moved below its 50-day moving average on July 22, 2026 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for AMSF crossed bearishly below the 50-day moving average on July 29, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In of 21 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where AMSF declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for AMSF entered a downward trend on August 11, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.067) is normal, around the industry mean (2.497). P/E Ratio (11.238) is within average values for comparable stocks, (16.901). AMSF's Dividend Yield (0.057) is considerably higher than the industry average of (0.023). P/S Ratio (1.571) is also within normal values, averaging (2.544).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. AMSF’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. AMSF’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 55, placing this stock worse than average.

Industry description

Specialty insurance typically caters to niche-markets, and covers items that are special or unique and/or items that are not typically covered under other insurance policies. Restoration or purchase of a one-of-a-kind collector’s item, high-value home, recreational vehicles, sailboat or even jet skis, horses and farms, all-terrain vehicle, funerals, museums and fine art collections are some examples– one or more of which are covered by a specialty insurance provider. In some cases, a specialty insurance could also complement someone’s existing auto, home and umbrella policies. Markel Corp, for Fidelity National Financial, Inc., Assurant, Inc. and Athene Holding Ltd. are examples of specialty insurance providers.

Market Cap

The average market capitalization across the Specialty Insurance Industry is 4.46B. The market cap for tickers in the group ranges from 518.61K to 12.78B. FNF holds the highest valuation in this group at 12.78B. The lowest valued company is PMIR at 518.61K.

High and low price notable news

The average weekly price growth across all stocks in the Specialty Insurance Industry was -5%. For the same Industry, the average monthly price growth was -5%, and the average quarterly price growth was -1%. ACT experienced the highest price growth at 3%, while OSG experienced the biggest fall at -18%.

Volume

The average weekly volume growth across all stocks in the Specialty Insurance Industry was -12%. For the same stocks of the Industry, the average monthly volume growth was 21% and the average quarterly volume growth was -43%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 54
P/E Growth Rating: 48
Price Growth Rating: 56
SMR Rating: 76
Profit Risk Rating: 54
Seasonality Score: -36 (-100 ... +100)
View a ticker or compare two or three
AMSF
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
Last 5 trading days
A.I. Advisor
published General Information

General Information

a provider of workers compensation insurance for businesses in hazardous industries

Industry SpecialtyInsurance

Profile
Details
Industry
Life Or Health Insurance
Address
2301 Highway 190 West
Phone
+1 337 463-9052
Employees
370
Web
https://www.amerisafe.com
Interact to see
Advertisement
Novo Nordisk (NVO) reports Q4 2025 earnings on February 4, 2026, with consensus estimates of $11.96 billion in revenue and $0.89 EPS, reflecting a moderation in GLP-1 growth. Eli Lilly (LLY) is expected to report around the same time, with projections of $17.87 billion in revenue and $6.99 EPS, driven by continued volume gains from Mounjaro and Zepbound.
Banco Santander (SAN) reports Q4 2025 earnings on February 4, 2026, following record nine-month attributable profit of €10.3 billion, up 11% year over year.
Uber (UBER) reports Q4 2025 earnings on February 4, 2026, with consensus estimates of $0.78 EPS and $14.32 billion in revenue, up about 20% year over year.
Qualcomm’s Q1 FY2026 report, covering the period ended December 28, 2025, arrives amid a pivotal shift in the semiconductor landscape. While handset growth moderates, the company is expanding in automotive, IoT, and AI-enabled devices.
UBS Group AG reports Q4 2025 earnings on February 4, 2026, with consensus EPS ranging $0.25–$0.67 and revenue around $11.62 billion, down YoY. HSBC Holdings plc reports Q4 earnings on February 25, 2026, with consensus EPS ~$1.57; Q3 showed resilient net interest income despite $1.4B in legal provisions.
Boston Scientific’s Q4 caps a transformative year, driven by ~15.5% organic growth from WATCHMAN, FARAPULSE electrophysiology, and MedSurg expansions. As a leader in minimally invasive devices, BSX’s results set the benchmark against Medtronic and Stryker—diversified medtech giants navigating tariffs, procedural rebounds, and innovation.
Arm, the leading provider of energy-efficient processor designs powering over 99% of smartphones and expanding into AI data centers, faces high scrutiny in Q3 FY2026 (ending Dec 31, 2025). After a strong Q2 with record royalty and licensing revenue, investors are focused on whether AI demand will continue to drive robust growth.
Datadog (DDOG) has come under pressure in recent sessions as volatility across the software sector weighs on sentiment ahead of earnings. Trading in the $108–120 range following a pullback from highs near $200, the stock reflects a disconnect between near-term market caution and resilient underlying fundamentals.
Starbucks shares have shown renewed strength in recent trading, rebounding from earlier lows within a 52-week range of $75.50 to $117.46. The recovery reflects improving comparable sales trends and a return to transaction growth, suggesting early progress from operational initiatives aimed at reconnecting with customers.
DoorDash holds a Strong Buy consensus from 33 analysts, with an average 12-month price target of $280.82, implying more than 40% upside from recent trading levels.
Amazon’s Q4 report capped a strong year marked by accelerating cloud growth, steady retail execution, and expanding advertising profitability. The results reinforced Amazon’s positioning as a core beneficiary of enterprise AI demand, particularly through AWS, while highlighting improving operating leverage across the broader business.
ConocoPhillips reported Q4 2025 adjusted EPS of $1.02, below consensus of $1.08, driven by weaker realized commodity prices.
ICE reported Q4 2025 net revenues of $2.5 billion, up 8% year-over-year, capping 20 consecutive years of record annual revenues at $9.9 billion.
Eli Lilly’s Q4 results highlight explosive growth from GLP-1 therapies, cementing leadership in obesity and diabetes. The company’s strong revenue beat and robust 2026 guidance illustrate high-growth pharma dynamics. Johnson & Johnson, in contrast, exemplifies a diversified healthcare strategy, combining pharmaceuticals, MedTech, and consumer health for steady expansion.
Eli Lilly (LLY), AbbVie (ABBV), and Merck (MRK) all reported strong Q4 2025 earnings, but the market reacted differently to each, reflecting variations in growth profiles, product concentration, and sector dynamics. AbbVie delivered Q4 revenue of $16.62 billion, up 10% year-over-year, with full-year revenue reaching $61.2 billion, an 8.6% increase. Adjusted EPS came in at $2.71, surpassing consensus, though shares dipped following the report amid ongoing Humira concerns
Novo Nordisk (NVO) reported Q4 2025 EPS of $1.02, surpassing estimates of $0.92, with revenue of $12.53B vs $11.99B expected. Full-year 2025 sales rose 10% at constant exchange rates (CER) to DKK 309B, but 2026 guidance anticipates a 5–13% decline at CER due to pricing pressures. Novartis (NVS) posted Q4 core EPS of $2.03, beating $1.99 estimates; net sales of $13.34B slightly missed consensus. FY sales grew 8%, with core EPS up 17% to $8.98.
MUFG (Mitsubishi UFJ Financial Group) posted Q3 FY2026 profits of ¥1.81 trillion, up 3.7% YoY, on track for its full-year target of ¥2.1 trillion. HSBC is set to report Q4 FY2025 earnings on Feb 25, 2026, with consensus EPS around $1.60; recent quarters showed resilient net interest income (NII) supported by Asia wealth growth.
Gogo shares continue to trade near 52-week lows around $4, weighed down by competitive threats from Starlink and slower-than-anticipated AVANCE system upgrades. William Blair downgraded the stock to Market Perform in December 2025, citing leverage concerns and intensifying rivalry in in-flight connectivity.
Quantum Computing Inc. completed a $110 million acquisition of Luminar Semiconductor on February 2, significantly strengthening its photonics and manufacturing capabilities. Shares have traded with elevated volatility, peaking near $12.70 in mid-January before retreating to the $9 range amid heavy volume.
ERII shares have remained resilient, trading near $15.47 ahead of Q4 and full-year 2025 earnings scheduled for February 25, 2026. Q3 2025 results exceeded expectations, with revenue of $32 million and EPS of $0.07, despite year-over-year declines tied to project timing.
AMERISAFE (AMSF) Reports +11.4% Premium Growth in Q2